Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article Free
space
 arrow  PDF of this article
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box Social Bookmarking
 Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter
What's this?
box PubMed
Articles in PubMed by Author:
 arrow  Savage, P. J.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ONGOING AND PROPOSED TRIALS

Cardiovascular Complications of Diabetes Mellitus: What We Know and What We Need To Know about Their Prevention

right arrow Peter J. Savage, MD

1 January 1996 | Volume 124 Issue 1 Part 2 | Pages 123-126

Cardiovascular disease is a major cause of morbidity and mortality in patients with non–insulin-dependent diabetes mellitus (NIDDM). With an increase in the number of older diabetic persons, an increase in U.S. minority populations with high rates of diabetes, and the proven success of new methods to reduce microvascular complications, the importance of diabetic macrovascular complications will increase. The relative effectiveness of different treatments to reduce the incidence of diabetic cardiovascular complications is poorly understood. In addition to relative efficacy, issues related to patient burden and the economic cost of different treatments must be considered. Some of the information needed to improve therapy will be available soon from ongoing clinical trials. Obtaining definitive answers to other questions, especially those related to the relative benefit of intensive glucose level control compared with control of other known cardiovascular disease risk factors, will require additional studies. Although several questions unique to diabetic patients remain unanswered, results of previous clinical trials done among largely nondiabetic participants can be used to develop interim recommendations for cardiovascular disease prevention. Until definitive guidelines for prevention are established, combining aggressive therapy for known cardiovascular disease risk factors with efforts to normalize the glucose level offers the best chance to reduce the higher risk for cardiovascular disease associated with NIDDM.

Author and Article Information
space

From the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. For the current author address, see end of text.
Note: This article is one of a series of articles comprising an Annals of Internal Medicine supplement entitled "Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus: The Fifth Regenstrief Conference." To view a complete list of the articles included in this supplement, please view its Table of Contents.
Requests for Reprints: Peter J. Savage, MD, Epidemiology and Biometry Program, DECA, Two Rockledge Center-Rm 8154, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Bethesda, MD 20892-7934.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
R. Scognamiglio, C. Negut, A. Ramondo, A. Tiengo, and A. Avogaro
Detection of Coronary Artery Disease in Asymptomatic Patients With Type 2 Diabetes Mellitus
J. Am. Coll. Cardiol., January 3, 2006; 47(1): 65 - 71.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
G. X. Brogan Jr, E. D. Peterson, J. Mulgund, D. L. Bhatt, E. M. Ohman, W. B. Gibler, C. V. Pollack Jr, M. E. Farkouh, and M. T. Roe
Treatment Disparities in the Care of Patients With and Without Diabetes Presenting With Non-ST-Segment Elevation Acute Coronary Syndromes
Diabetes Care, January 1, 2006; 29(1): 9 - 14.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Scognamiglio, C. Negut, A. Ramondo, A. Tiengo, and A. Avogaro
Detection of Coronary Artery Disease in Asymptomatic Patients With Type 2 Diabetes Mellitus
J. Am. Coll. Cardiol., December 13, 2005; (2005) j.jacc.2005.10.008v1.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
B. E.K. Klein, R. Klein, P. E. McBride, S. E. Moss, R. J. Prineas, and J. O. Reinke
Electrocardiographic Abnormalities in Individuals With Long-Duration Type 1 Diabetes
Diabetes Care, January 1, 2005; 28(1): 145 - 147.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T.-M. Lee and T.-F. Chou
Impairment of Myocardial Protection in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 531 - 537.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
W. A. Hsueh and R. E. Law
PPAR{gamma} and Atherosclerosis: Effects on Cell Growth and Movement
Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 1891 - 1895.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. R. Collins, W. P. Meehan, U. Kintscher, S. Jackson, S. Wakino, G. Noh, W. Palinski, W. A. Hsueh, and R. E. Law
Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 365 - 371.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D.K McGuire, H Emanuelsson, C.B Granger, E Magnus Ohman, D.J Moliterno, H.D White, D Ardissino, J.W Box, R.M Califf, and E.J Topol
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study
Eur. Heart J., November 1, 2000; 21(21): 1750 - 1758.
[Abstract] [PDF]


Home page
Eur Heart JHome page
N Suskin, R.S McKelvie, R.J Burns, R Latini, D Pericak, J Probstfield, J.L Rouleau, C Sigouin, C.B Solymoss, R Tsuyuki, et al.
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure
Eur. Heart J., August 2, 2000; 21(16): 1368 - 1375.
[Abstract] [PDF]


Home page
Am. J. Clin. Nutr.Home page
J. W Anderson, L. D Allgood, J. Turner, P. R Oeltgen, and B. P Daggy
Effects of psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia
Am. J. Clinical Nutrition, October 1, 1999; 70(4): 466 - 473.
[Abstract] [Full Text] [PDF]


Home page
Fam PractHome page
W. J. de Grauw, E. H van de Lisdonk, R. R. Behr, W. H. van Gerwen, H. J. van den Hoogen, and C. van Weel
The impact of type 2 diabetes mellitus on daily functioning
Fam. Pract., April 1, 1999; 16(2): 133 - 139.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Hattori, S. Hattori, and K. Kasai
Troglitazone Upregulates Nitric Oxide Synthesis in Vascular Smooth Muscle Cells
Hypertension, April 1, 1999; 33(4): 943 - 948.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
A. J Krentz
Fortnightly Review: Insulin resistance
BMJ, November 30, 1996; 313(7069): 1385 - 1389.
[Abstract] [Full Text]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 1996 by the American College of Physicians.